Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > BioImmune ... Their path to Breakthrough designation

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on May 04, 2022 12:28pm

143 Views

Post# 34655361

RE:RE:RE:BioImmune ... Their path to Breakthrough designation

I remember the sesen comparison before this trial started or a bit after. Anyway I believe this was part of the reasoning behind doing 2 doses. Oh yeah it was the PowerPoint presentation done by the good doctor. Paraphrase. There is medical precedent for 2 doses Theres is also commercial benefit for 2 doses. Aka. $$$. 1 dose might not be attractive enough to say that photodynamic have evolved. 2 doses with no safety concerns meaning 3 or 4 possibilities. Maybe Novartis Roche etc might like that more. Let's cut right through it. Cheers

ScienceFirst wrote: More treatments than our 2-doses treatment.

From the cllnical trial record:

Drug: N-803 and BCG
BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction).

After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3.

Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.

Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.